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PURPOSE. Chronic central serous chorioretinopathy (cCSC) is characterized by fluid
accumulation between photoreceptors and the retinal pigment epithelium of which the
cause is unknown. Associations with steroid use, stress, pregnancy, and the male sex suggest a
role for the steroid hormone system in the disease. Here, we performed a comprehensive
analysis of the steroid hormone system in active cCSC.
METHODS. Serum hormone levels of 17 steroid hormones were measured in 46 male Caucasian
patients with active cCSC and 46 male Caucasian age-matched controls using the AbsoluteIDQ
stero17 kit.
RESULTS. Elevated levels of androsterone, estrone, etiocholanolone, and androstenedione were
observed in cCSC patients compared with controls. Median hormone levels in cCSC patients
versus controls, respectively, were as follows: androsterone, 0.84 ng/mL (interquartile range
[IQR] ¼ 0.61–1.06) versus 0.69 ng/mL (IQR ¼ 0.48–0.96, P ¼ 0.031); estrone, 0.12 ng/mL
(IQR ¼ 0.10–0.15) versus 0.10 ng/mL (IQR ¼ 0.08–0.11; P ¼ 0.0048); etiocholanolone, 0.19
ng/mL (IQR ¼ 0.15–0.29) versus 0.13 ng/mL (IQR ¼ 0.099–0.20, P ¼ 0.0061). Mean levels of
androstenedione were 3.10 ng/ml (SD ¼ 1.03) versus 2.55 ng/mL (SD ¼ 0.95), in cCSC
patients versus controls, respectively. Additionally, Spearman’s correlations between
aldosterone and 11-deoxycortisol, androsterone, DHEA, DHEAS, and E1 differed between
cCSC patients and controls, as well as between andosterone and E1, and between DHT and
17OHP.
CONCLUSIONS. We present a comprehensive overview of the status of the steroid hormone
system in active cCSC. Levels of four hormones were elevated in cCSC patients compared
with controls, and the relationships between steroid hormones was altered, indicating that
the balance in the steroid hormone system is altered in cCSC patients.
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Central serous chorioretinopathy (CSC) is a multifactorialretinal disease characterized by fluid accumulation be-
tween the photoreceptors and the RPE, leading to vision
impairment.1–3 The etiology of CSC is currently unknown, and
treatment options are limited. Two main forms of CSC have
been described: acute CSC and chronic CSC (cCSC). Acute CSC
usually resolves spontaneously, whereas patients with cCSC
have persisting complaints or multiple recurrent episodes of
fluid accumulation accompanied with permanent loss of visual
acuity and more extensive atrophic RPE alterations.1,3 CSC is
more frequent in men (~80% of patients) and has been
associated with stress, the use of steroids, type A personality,
and pregnancy,1–3 suggesting an important role for the steroid
hormone system in the disease.
Steroid hormones regulate a large number of physiologic
processes, such as sex differentiation, metabolism, and immune
responses.4 To date, only a limited number of studies have
investigated hormone levels in CSC patients. The most widely
studied hormone in CSC is cortisol, with more than 11
published studies,5–15 aldosterone was measured in 2 stud-
ies,7,16 testosterone levels were measured in 4 studies,6,7,9,11
and dehydroepiandrosterone (DHEA), and dehydroepiandros-
terone sulfate (DHEAS) were both described in only one study
each.7,17 However, results between studies regarding significant
associations of cortisol or testosterone levels with cCSC were
not consistent, showing associations in some studies but not in
others.5–15 Notably, these studies focused only on a limited
number of hormones, whereas it is known that many complex
interactions exist between steroid hormones and that they are
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highly correlated.4 A comprehensive analysis of the steroid
hormone system would not only provide information on
differences in individual steroid hormone levels but would also
allow for the assessments of interactions between hormones.
Therefore, to better understand the role of the hormone
system and to observe possible imbalances in this system in
cCSC, we performed a pilot study in which we simultaneously
measured 17 different steroid hormones in serum samples of
46 patients with active cCSC and 46 age- and sex-matched
controls. With this comprehensive analysis, we aimed to
increase our knowledge on the status of the steroid hormone
system in cCSC patients to gain more insight into the
mechanisms underlying the disease.
MATERIALS AND METHODS
Patients and Control Individuals
In this multicenter study, we included 46 Caucasian patients
with cCSC from two different university hospitals. As controls,
46 age- and sex-matched Caucasian individuals from the
EUGENDA database were used (www.eugenda.org). In total,
16 cCSC patients and 36 controls were collected at the
Radboud University Medical Center (Nijmegen, The Nether-
lands), and 30 cCSC patients and 10 controls were collected at
the University Hospital of Cologne (Cologne, Germany).
Individuals who reported steroid or eplerenone/spironolac-
tone use within the last 6 months at the moment of blood
withdrawal were excluded from the study.
The diagnosis of active cCSC was based on multimodal
grading of images obtained via color fundus photographs,
optical coherence tomography, fluorescein angiography (FA),
and indocyanine green angiography (ICGA) by two indepen-
dent graders (LA, VS). Active cCSC was defined upon the
following criteria18: (1) one or more regions of active leakage
(focal or diffuse) in FA/ICGA with RPE alterations visible in FA/
ICGA, (2) visible subretinal fluid on spectral domain optical
coherence tomography (SD-OCT), and (3) subjective visual
symptoms and/or SRF on SD-OCT present for at least 6 weeks.
Patients with signs of prolonged disease with structural RPE
changes such as extensive RPE alterations (‡5 disc areas) and/
or intraretinal fluid were excluded. None of the controls and
cCSC patients showed signs of other retinal diseases (e.g.,
drusen, AMD, former or present choroidal neovascularization,
myopic degeneration, dome-shaped maculopathy, choroidal
hemangioma, vitreomacular traction, and diabetic macular
edema) on OCT, fundus photography, or FA/ICGA. Disease
duration was a minimal of 2 months for all patients.
Written informed consents were obtained for all individuals
participating in this study. This study was performed according
to the guidelines of the Declaration of Helsinki and the local
ethic committees of the participating hospitals approved the
study.
Steroid Measurements
Serum samples were collected using a standardized coagula-
tion and centrifugation protocol, and samples were stored at
808C within 1 hour after collection. Time of blood withdrawal
was recorded for the cCSC patients as they were collected
specifically for this study, but was not known for the
EUGENDA control samples, which were collected previously
for the EUGENDA database. For each participant, an aliquot of
frozen serum (500 lL) was shipped to Biocrates Life Sciences
(Innsbruck, Austria), and 17 different steroid hormones were
measured using the AbsoluteIDQ stero17 assay. The 17 steroids
include glucocorticoids (cortisol, cortisone, and 11-deoxycor-
tisol), mineralocorticoids (aldosterone, corticosterone, and
deoxycorticosterone [DOC]), progestogens (17a-hydroxypro-
gesterone [17-OHP] and progesterone), estrogens (estrone [E1]
and estradiol [E2]), and androgens (androstenedione, andros-
terone, dehydroepiandrosterone [DHEA], dehydroepiandros-
terone sulfate [DHEAS], dihydrotestosterone [DHT],
etiocholanolone, and testosterone). Measurements of the 17
hormones were obtained from Biocrates in an Excel sheet
along with a corresponding data report.
Statistical Analysis
All statistical analyses were conducted using SPSS (IBM, version
25). Hormone levels in cCSC patients and controls were tested
for normality with the Shapiro-Wilk test. Levels of normally
distributed hormones were compared between cCSC patients
and controls with an independent sample t-test, whereas non-
normally distributed hormones were tested with a Mann-
Whitney U test. The levels of associated steroids (P < 0.05)
were compared between collection sites (Cologne and
Nijmegen) with the same tests, depending on the normality
of the distribution of the individual hormones. Additionally,
levels of the associated steroids were compared between time
of blood withdrawal with a Kruskal-Wallis test with the
following hourly bins: 0800 to 0900, 0900 to 1000, 1000 to
1200, 1200 to 1300, and 1400 and 1500 hours.
Because all steroid hormones are derived from cholesterol
and are thus highly correlated, the Spearman’s q rank
correlation between the different steroid hormones was
calculated. The correlation coefficients of cCSC patients and
the control individuals were compared by first transforming
the q correlations into Z-scores using the Fisher Z transforma-
tion, and then comparing the differences divided by the SE of
the differences to obtain a P value as proposed by Cohen et
al.19
RESULTS
This study included 46 Caucasian male patients with an active
episode of cCSC and 46 Caucasian unaffected male controls
collected at two university hospitals. The mean age of the
included patients was 50 (range, 28–72) years, and the mean
age of the age-matched controls was 50 (range, 22–72) years,
which was not significantly different. Patient demographics are
presented in Table 1.
Fourteen of the 17 steroid hormones were successfully
measured, whereas 3 steroids had measurements outside of the
TABLE 1. Demographics and Multimodal Grading of cCSC
Radboud
University
Medical Center
(N ¼ 16)
University
Hospital
of Cologne
(N ¼ 30)
Age (mean 6 SD) 51.44 6 8.88 48.77 6 11.32
Disease duration (mean 6 SD) 9.19 6 8.64 43.80 6 49.29
Patients with CSC less than 6 mo 9 8
Patients with CSC 6 mo to 1 y 3 5
Patients with CSC more than 1 y 4 17
Leakage type (FA/ ICGA) (n)
One focal hotspot 3 14
‡2 focal hotspots 6 4
Diffuse leakage 9 12
RPE alteration (n) (AF/FA/FP) 16 30
Subretinal fluid (n) (SD-OCT) 16 30
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limit of detection (LOD) in some samples (aldosterone [10
samples; 10.8%], estradiol [E2] [1 sample; 1.1%], etiocholanol-
one [11 samples; 12.0%]). The distribution of samples that
ranged outside of the LOD was equal between cCSC patients
and controls. All hormone levels, except for androstenedione,
cortisone, and DHEAS, showed deviation from a normal
distribution in either cCSC patients or controls; therefore,
nonparametric tests were used for these hormones, and
median levels with interquartile ranges (IQRs) are described.
Higher levels of androsterone, androstenedione, E1, and
etiocholanolone were observed in cCSC patients compared
with controls (Fig. 1; Table 2). Median levels for androsterone
were 0.84 ng/mL (IQR¼ 0.61–1.06) in cCSC patients and 0.69
ng/mL (IQR ¼ 0.48–0.96) in controls (P¼ 0.031). The median
levels of E1 in cCSC patients were 0.12 ng/mL (IQR ¼ 0.10–
0.15) and 0.10 ng/mL (IQR ¼ 0.08–0.11) in controls (P ¼
0.0048). Median concentration of etiocholanolone was 0.19
ng/mL (IQR ¼ 0.15–0.29) in cCSC patients and 0.13 ng/mL
(IQR ¼ 0.099–0.20) in controls (P ¼ 0.0061). Finally, mean
androstenedione levels were 3.10 ng/mL (SD ¼ 1.03) in cCSC
patients and 2.55 ng/mL (SD ¼ 0.95) in controls (P¼ 0.0094).
Disease duration and age of cCSC patients had no impact on
the levels of androsterone, androstenedione, E1, and etiochol-
anolone (P > 0.1 for all). No difference was observed between
samples collected from Nijmegen or Cologne for the associated
steroids (Supplementary Table S1), and no association was
observed between levels of these four steroids and the time of
blood withdrawal (Supplementary Table S2).
Next, the relationship between steroids was investigated in
cCSC patients and controls by calculating Spearman’s q
correlations between all measured steroids. Numerous steroid
hormones were highly correlated in both the cCSC patients
and controls (Fig. 2). Comparison of the Spearman’s correla-
tion coefficients between cCSC patients and controls identified
a difference in correlations for aldosterone with androsterone
(0.316 vs. 0.379, P¼ 0.00076), DHEA (0.029 vs. 0.445, P¼
0.019), DHEAS (0.117 vs. 0.333, P ¼ 0.031), E1 (0.381 vs.
0.085, P¼0.024), and 11-deoxycortisol (0.208 vs.0.255, P¼
0.029) in controls and cCSC patients, respectively. Additionally,
a difference in the correlation of androsterone with E1 (0.613
vs.0.182, P¼0.014) and DHT with 17-OHP (0.100 vs. 0.538,
P¼0.0011) was observed between controls and cCSC patients,
respectively (Table 3; Fig. 2, red bordered squares). The four
steroids associated with cCSC were positively correlated in all
groups (Supplementary Fig. S1).
DISCUSSION
To obtain a comprehensive overview of the entire steroid
hormone system in cCSC, we studied 17 steroids in 46 patients
with active cCSC and 46 age-matched controls. We measured
elevated levels of androsterone, androstenedione, estrone, and
FIGURE 1. Hormone levels associated with cCSC. The panels indicate the absolute hormone levels measured in cCSC patients (cases) in red and
controls in green. For androstenedione, error bars indicate mean and SD, whereas for the other hormones, the median and interquartile ranges are
depicted. Values for mean and medians are presented in Table 2.
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etiocholanolone in patients with active cCSC compared with
controls. Additionally, alterations in the balance of the steroid
hormone system were observed in cCSC patients, mainly
involving relationships of aldosterone with other steroids.
Our study is the first that comprehensively evaluated all 17
steroid hormones in a cCSC case-control cohort. To date, a
limited number of studies have been performed on steroid
hormone imbalances in cCSC patients, and these studies
focused on either single measurements or at most on four
steroids simultaneously. Association results were variable
between studies and reported hormone levels also varied
greatly between studies. Some associations with testosterone,
and morning, evening or 24-hour cortisol levels have been
reported,5,7,9,12,14 but other studies did not confirm these
results.9,10,13 Aldosterone, DHEA, and DHEAS were measured,
but no associations with cCSC were observed in the studies
investigating these hormones thus far.7,17
To our knowledge, no studies have been published that
have evaluated levels of androsterone, androstenedione, E1,
and etiocholanolone in cCSC, and our study is first describing
elevated levels of these hormones in cCSC patients. Andros-
terone, androstenedione, etiocholanolone, and estrone are
important products of the sex hormone branch of the steroid
hormone system. Androstenedione, androsterone, and etio-
cholanolone are weak androgens and mainly function as
precursors or metabolites for testosterone (Fig. 3).4 However,
androsterone and etiocholanolone have additional neuroste-
roid properties acting on the GABAA receptor and are able to
cross to the blood–brain barrier to prevent seizures.20,21
Androstenedione is the main precursor of testosterone and
estrone.4 Estrone is a weak estrogen hormone that can readily
be converted to estradiol, has binding affinity to the estrogen
receptors ERa and ERb, and its levels are known to be
increased in the blood of postmenopausal women.22 Currently,
the role of these hormones in the etiology of cCSC is still
unknown. Future studies might focus on determining the
influence of elevated levels of these hormones on the RPE and
choroid using for example cell models.
We assessed the steroid hormone system as a whole by
investigating relationships between the different hormones.
Interestingly, we observed several altered correlations between
the measured hormones when comparing controls and cCSC
patients. In controls, a positive correlation was observed
between aldosterone, androsterone, and estrone. In cCSC
patients, a negative correlation for aldosterone with andros-
terone was observed, and the correlation with estrone with
both aldosterone and androsterone was lost. Additionally, in
cCSC patients, DHEA, DHEAS, and 11-deoxycortisol were
negatively correlated with aldosterone, and DHT was negative-
ly correlated with 17-OHP, whereas these correlations were not
observed in controls. Although aldosterone itself was not
associated with cCSC in this study, its altered relationship with
multiple other hormones suggests an altered balance in the
steroid hormone system in cCSC patients. In light of the
current clinical trials targeting the mineralocorticoid receptor
(the binding site of aldosterone), this observation might be
clinically relevant. In future studies, follow-up measurements
of patients with active cCSC when they either have spontane-
ously resolved, have responded to treatment (micropulse laser,
photodynamic therapy, or eplerenone) or have persisting
complaints might be informative to determine whether
alterations in the hormone level balance could be used as
predictor of disease status or treatment response, or might in
itself be a target for treatment.
In this study, several steps were performed to minimize
confounding by factors that are known to influence steroid
levels. First, to homogenize the dataset we included only males
in this study, because the disease is most prevalent men
(9.9:100,000 vs. 1.7:100,000 in women).23 Because the inves-
tigated steroids are product of the sex hormone branch, steroid
dysbalance for female cCSC patients should be investigated in
future studies. To further homogenize our cohort, the controls
used in this study were age-matched with the cCSC patients.
Also, all individuals that reported the use of medication
containing steroids or used a mineralocorticoid receptor
antagonist within the last 6 months prior to blood withdrawal
TABLE 2. Association Results of Steroids in 46 cCSC Patients Compared With 46 Controls
Non-Normally
Distributed Hormones
Concentration in ng/mL
Mann-Whitney U
2-Sided P Value
Controls cCSC Patients
Median, ng/mL IQR Median, ng/mL IQR
11-Deoxy-corticosterone 0.070 (0.053–0.11) 0.088 (0.052–0.13) 0.323
11-Deoxycortisol 0.55 (0.35–0.9) 0.59 (0.41–1.26) 0.492
17a-Hydroxyprogesterone (17-OHP) 2.11 (1.6–2.64) 2.14 (1.63–2.63) 0.854
Aldosterone 0.14 (0.085–0.21) 0.16 (0.13–0.23) 0.303
Androsterone 0.69 (0.48–0.96) 0.84 (0.61–1.06) 0.031
Corticosterone 5.12 (3.048–8.49) 4.96 (2.65–9.82) 0.975
Cortisol 259.35 (209.65–360.13) 275.60 (232.05–357.35) 0.331
Dehydroepiandrosterone (DHEA) 10.05 (5.15–15) 11.25 (7.63–16.35) 0.414
Dihydrotestosterone (DHT) 1.28 (1.04–1.73) 1.24 (0.90–1.81) 0.468
Estrone (E1) 0.10 (0.080–0.11) 0.12 (0.10–0.15) 0.0048
Estradiol (E2) 0.067 (0.052–0.081) 0.060 (0.052–0.083) 0.654
Etiocholanolone 0.13 (0.099–0.20) 0.19 (0.15–0.29) 0.0061
Progesterone 0.17 (0.13–0.26) 0.16 (0.12–0.25) 0.797
Testosterone 14.75 (10.40–18.40) 14.50 (10.8–17.45) 0.587
Normally Distributed Hormones Mean, ng/mL SD Mean, ng/mL SD Independent t-Test P Value
Androstenedione 2.55 0.95 3.10 1.029 0.0094
Cortisone 61.78 16.56 68.01 13.62 0.052
Dehydroepiandrosterone sulphate (DHEAS) 5064.82 3030.96 5759.03 2638.17 0.244
* Bold values indicate statistical significance, P < 0.05.
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were excluded. Additionally, we excluded patients that are
suspicious for the presence of choroidal neovascularization
(CNV), such as patients with intraretinal fluid; however, no OCT
angiography was performed. In the future studies, we suggest to
extend phenotyping with OCT angiography imaging to exclude
possible CNV. Finally, for the cCSC-associated hormones, we
confirmed that levels were not dependent on time at blood
withdrawal and did not differ between recruitment sites.
Here, by simultaneously measuring 17 components of the
steroid hormone system in a group of active cCSC patients, the
status of the hormone system could be investigated. This
approach allowed us to describe elevated single hormone
levels in addition to altered relationships between various
hormones in cCSC patients compared with controls. Even
though our study is one of the larger studies on steroid
measurements in cCSC patients performed to date, the current
sample size is still limited, and future studies should focus on
replication of the current study in an independent cCSC
cohort. Also, as most steroids have a diurnal rhythm, future
studies should include both morning and evening samples of
the same individual, as well as 24-hour urine measurements.
Furthermore, steroid dysbalance should be investigated for
acute CSC patients in future studies, as these patients might
show different hormonal alterations than chronical patients.
Finally, as only male cCSC patients were included in this study,
measurements of the 17 steroids and the hormone system
balance in female cCSC patients could provide new insights on
sex-specific differences in the disease.
CONCLUSIONS
In this study, we measured elevated levels of androsterone,
androstenedione, E1, and etiocholanolone in Caucasian pa-
FIGURE 2. Spearman’s correlations between steroid hormones in cCSC patients and controls. Left: correlations are depicted as observed in the
controls, whereas correlations in cCSC patients are found on the right. Colors indicate positive (blue) and negative (red) correlations between the
different hormones, and significant correlations are indicated with an asterisk. Red bordered squares highlight correlations that are significantly
different between cCSC patients and controls (Table 3).
TABLE 3. Difference in Correlations of Steroid Hormones Between cCSC Patients and Controls
Correlation
Controls cCSC Patients
Delta q Delta Z P ValueSpearman q Correlation P Value Spearman q Correlation P Value
Aldosterone-11-deoxycortisol 0.208 0.198 0.255 0.103 0.463 2.188 0.029
Aldosterone-androsterone 0.316 0.047 0.379 0.013 0.695 3.367 0.00076
Aldosterone-DHEA 0.029 0.859 0.445 0.0031 0.474 2.354 0.019
Aldosterone-DHEAS 0.117 0.473 0.333 0.031 0.450 2.152 0.031
Aldosterone-estrone (E1) 0.381 0.0153 0.085 0.592 0.466 2.255 0.024
Estrone (E1)-androsterone 0.613 6.00 3 106 0.182 0.227 0.431 2.456 0.014
DHT-17OHP 0.100 0.510 0.538 1.13 3 104 0.638 3.255 0.0011
* Bold values indicate statistical significance, P < 0.05.
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tients with an active episode of cCSC compared with controls.
Additionally, we observed altered correlations between hor-
mones in cCSC patients, mainly with aldosterone, indicative of
an altered hormone system balance in individuals with cCSC.
This study provides new insights into the status of the steroid
hormone system in active cCSC and suggests new leads for
future studies into the role of steroid hormones in cCSC. These
studies should include larger sample sizes and multiple
measure points per patients to evaluate the potential
predictive value of the hormone system balance for active
phases of cCSC and on whether restoring steroid hormone
balance might be an avenue for treatment of cCSC.
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